The FDA reveals that 56,000 malfunctions associated with surgical staplers weren’t reported through its traditional public reporting system.
As part of his plan to tamp down drug pricing, President Donald Trump wants pharmaceutical companies to provide cost information in drug ads — just like side effects.
What to know about PBMs and rebates ahead of the Senate drug price hearing on — you guessed it — PBMs.
A Kaiser Health News database shows that $58 million flowed from drugmakers to patient groups running national ads.
President Donald Trump and FDA officials have pointed to a surge in generic drug approvals, but a data analysis indicates almost half haven’t reached the market.
Patients are often forced into using brand names because drug formularies favor them over cheaper competitors.
The Food and Drug Administration is supposed to inspect all factories, foreign and domestic, that produce drugs for the U.S. market. But a KHN review of thousands of FDA documents — inspection records, recalls, warning letters and lawsuits — reveals how drugs that are poorly manufactured or contaminated can reach consumers.
A probe by the Government Accountability Office cites breakdowns in the Food and Drug Administration program that approves drugs for rare diseases.
One of the most popular electronic health records software systems used by hospitals, Epic Systems, can delete records or require cumbersome workarounds when clocks are set back for an hour, prompting many hospitals to opt for paper records for part of the night shift.
Drugmakers’ contributions to lawmakers have peaked as surging drug prices emerge as a hot-button political issue. In the past decade, members of Congress have received nearly $79 million from 68 pharma PACs. And the giving crosses the aisle: In California, seven of the top 10 beneficiaries are Democrats — though Kevin McCarthy, the Republican House majority leader, tops other Golden State lawmakers in Congress by a wide margin.